Global  

Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod

DNA Wednesday, 16 September 2020 ()
The Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine.
0
shares
ShareTweetSavePostSend
 
Video Credit: HT Digital Content - Published
News video: Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon

Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon 01:19

Director General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being manufactured by Cadila Healthcare and Bharat Biotech have completed the first phase of the trial while...

You Might Like


💡 One News Page Knowledge: Other News Mentions

Serum Institute of India Serum Institute of India Indian biotechnological company, vaccine manufacturer

Phase 3 human clinical trial of Oxford vaccine begins in Pune

The phase-III human clinical trial of the Covid-19 vaccine being developed by Oxford University, and manufactured by the Serum Institute of India (SII), began at..
IndiaTimes
Covid update: 1,500 crore vaccine doses; onion export ban; Oct-Nov warning [Video]

Covid update: 1,500 crore vaccine doses; onion export ban; Oct-Nov warning

From the CEO of the world's largest vaccine manufacturer commenting on the possible timeline of the final vaccine reaching every person on the planet, to the World Health Organisation warning that the months of October and November 2020 could be 'tougher' - here are the top news updates on the Covid-19 pandemic. Adar Poonawalla, chief executive of Serum Institute of India reportedly said that it might take 4-5 years for the vaccine to reach everyone. He estimated that around 1,500 crore vaccine doses would be required to inoculate everyone if the final vaccine is a 2-dose drug. Meanwhile, the Government of India banned the export of onions after a 30% jump in export of the kitchen staple in the April-July 2020 period. Over a dozen Members of Parliament were found to be Covid positive on the day the central legislative body convened for its monsoon session. In Delhi, the deputy Chief Minister, Manish Sisodia, tested positive on the day that the Chief Minister of neighbouring Haryana, Manohar Lal Khattar, finally recovered from the disease. Watch the full video for the other top updates on the spread of the Sars-CoV-2 coronavirus.

Credit: HT Digital Content    Duration: 02:18Published

Coronavirus disease 2019 Coronavirus disease 2019 Infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2

Birmingham crash witnesses sought as injured man has Covid-19

A handful of people had close contact with a man hit by a car who has tested positive for Covid-19.
BBC News
Nicola Sturgeon: R number possibly as high as 1.6 in Scotland [Video]

Nicola Sturgeon: R number possibly as high as 1.6 in Scotland

Nicola Sturgeon said the R number in Scotland – the average number of otherpeople infected with the virus by each person with Covid-19 – could nowpossibly be as high as 1.6. Speaking at the start of First Minister’sQuestions at Holyrood, she said the latest figures showed why the ScottishGovernment had announced further “tough measures” aimed at curbingcoronavirus.

Credit: PA - Press Association STUDIO    Duration: 01:30Published
Why Iraqi COVID doctors fear for their safety [Video]

Why Iraqi COVID doctors fear for their safety

Iraqi doctor Tariq Al-Sheibani remembers little else beyond cowering on the ground as a dozen relatives of a patient, who had just died of COVID-19, beat him unconscious. Lauren Anthony.

Credit: Reuters Studio    Duration: 02:17Published

AstraZeneca British-Swedish pharmaceutical company

Oxford Covid vaccine: AstraZeneca still waiting for FDA nod to resume US trial

AstraZeneca is still waiting for the U.S. drug regulator to approve the restart of the clinical trial of its potential COVID-19 vaccine in the United States..
WorldNews
J&J launches final study of COVID-19 vaccine [Video]

J&J launches final study of COVID-19 vaccine

The drug giant said it would begin a stage three trial of a single-shot vaccine, which could prove easier to administer than rivals that require two inoculations. This report produced by Zachary Goelman.

Credit: Reuters - Politics    Duration: 01:09Published

Covid 19 coronavirus: Mystery illness that stopped vaccine trial

A trial participant for a promising Covid-19 vaccine suffered from mysterious neurological symptoms including limb weakness or "changed sensation", new research..
New Zealand Herald

AstraZeneca COVID-19 Vaccine Trial In US On Hold Until Midweek: Report

AstraZeneca's COVID-19 vaccine trial remains on hold in the United States pending a U.S. investigation into a serious side effect in Britain even as other trials..
WorldNews

Drugs Controller General of India organization

COVID-19: DCGI approves CSIR's paper-based testing kit [Video]

COVID-19: DCGI approves CSIR's paper-based testing kit

Council of Scientific and Industrial Research on September 20 informed that Drugs Controller General of India has approved CSIR's paper-based testing kit called Feluda for COVID-19. CSIR, Director General S Mande said, "Our Delhi CSIR lab's been working on studying CRISPR-Cas immunity. They have experience of working in this particular area before COVID-19 and could repurpose the thing for COVID and developed a paper-based testing kit called Feluda and got formal approval from DCGA. Mande further explained the functioning of the paper based test. "It's different as RTPCR detects RNA and amplifies it using a polymerase chain reaction that is costly. This paper-based test also detects RNA but by a CRISPR guided system. The paper lights up if there is any virus RNA to show a sample is positive, in 45 minutes," he added.

Credit: ANI    Duration: 02:43Published

Serum Institute of India gets DCGI nod to resume clinical trial of Oxford Covid-19 vaccine

Drugs Controller General of India (DCGI) Dr V G Somani on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19..
IndiaTimes
COVID-19: Oxford vaccine's late stage trials to start in a week in India, says ICMR [Video]

COVID-19: Oxford vaccine's late stage trials to start in a week in India, says ICMR

Director General of Indian Council of Medical Research, Dr Balram Bhargava on August 04 stated that Oxford vaccine, being manufactured by Serum Institute of India, got approval for phase 2 and 3 clinical trials which are starting within a week at 17 sites. Earlier, the Drugs Controller General of India (DCGI) has given approval to Serum Institute of India (SII), Pune, to conduct Phase II and III clinical trials of Oxford vaccine.

Credit: ANI    Duration: 02:24Published

Related videos from verified sources

UK will deliberately infect vaccine volunteers: report [Video]

UK will deliberately infect vaccine volunteers: report

Britain is planning to host clinical trials where volunteers are deliberately infected with the new coronavirus to test the effectiveness of vaccine candidates, the Financial Times reported on..

Credit: Reuters Studio     Duration: 01:22Published
Johnson & Johnson's COVID-19 Vaccine Enters Phase 3 US Trials [Video]

Johnson & Johnson's COVID-19 Vaccine Enters Phase 3 US Trials

The drugmaker made the announcement on Wednesday, joining the ranks of Pfizer and Moderna who have been in Phase 3 trials since July.

Credit: Cover Video STUDIO     Duration: 01:22Published
COVID-19 vaccine round-up: Johnson & Johnson begins Phase 3 trials in the United States [Video]

COVID-19 vaccine round-up: Johnson & Johnson begins Phase 3 trials in the United States

A large scale trial has kicked off today. Johnson & Johnson's coronavirus vaccine began its Phase 3 clinical trials. This is the fourth COVID-19 vaccine candidate to enter the final stage here in the..

Credit: WXYZ Detroit     Duration: 03:41Published

Related news from verified sources

Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod

The Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the...
DNA

Phase 3 human clinical trial of Oxford vaccine begins in Pune

The phase-III human clinical trial of the Covid-19 vaccine being developed by Oxford University, and manufactured by the Serum Institute of India (SII), began at...
IndiaTimes

Phase 3 trial of Oxford vaccine from next week

The phase-III human clinical trial of the Covid-19 vaccine developed by Oxford University and being manufactured by the Serum Institute of India (SII) will begin...
IndiaTimes Also reported by •Hindu

Tweets about this